A 340B pharmacy is a pharmacy that dispenses prescription drugs purchased at steep discounts through the federal 340B Drug Pricing Program. The program requires drug manufacturers to sell outpatient medications to eligible healthcare organizations at 25% to 50% below typical costs, and these organizations use in-house or contracted retail pharmacies to get those lower-cost drugs to patients. The program exists to stretch limited resources at hospitals and clinics that serve large numbers of low-income and uninsured people.
How the 340B Program Works
Congress created the 340B program to help safety-net healthcare providers afford medications for vulnerable populations. Drug manufacturers that want their products covered by Medicaid and Medicare Part B must agree to sell covered outpatient drugs to qualifying organizations at discounted ceiling prices. That ceiling price is calculated quarterly using a formula: the average manufacturer price minus a rebate amount determined by federal law. If the math results in a price below one cent, the floor is set at $0.01 per unit.
The practical result is that a hospital or clinic enrolled in 340B buys the same medications other providers buy, but at a fraction of the cost. The organization can then dispense those drugs to eligible patients through its own pharmacy or through a contract with an outside retail pharmacy. The difference between what the organization paid for the drug and what it receives in reimbursement from insurance generates revenue that the organization is expected to reinvest in patient care.
Which Organizations Qualify
Not every hospital or clinic can participate. The Health Resources and Services Administration (HRSA) maintains specific categories of eligible “covered entities,” and each must register and meet ongoing requirements. The qualifying types fall into four broad groups:
- Federally qualified health centers: community health centers, look-alikes, Native Hawaiian health centers, and tribal and urban Indian health centers
- Ryan White HIV/AIDS Program grantees: organizations receiving federal funding for HIV/AIDS care
- Hospitals: disproportionate share hospitals (those serving a high percentage of low-income patients), children’s hospitals, critical access hospitals, free-standing cancer hospitals, rural referral centers, and sole community hospitals
- Specialized clinics: black lung clinics, hemophilia treatment centers, Title X family planning clinics, sexually transmitted disease clinics, and tuberculosis clinics
The common thread is that these organizations serve populations who might otherwise go without care. Disproportionate share hospitals, for example, qualify specifically because a large share of their patients are on Medicaid or are uninsured.
In-House vs. Contract Pharmacies
A 340B pharmacy can take two forms. Some covered entities operate their own on-site pharmacy, purchasing discounted drugs directly and dispensing them to patients who walk in. This is the most straightforward model.
The second form is a contract pharmacy. A covered entity signs a written agreement with one or more outside retail pharmacies, which then dispense 340B-priced drugs to the entity’s eligible patients. This arrangement is common because many clinics, especially smaller rural ones, don’t have the infrastructure to run their own pharmacy. HRSA requires the covered entity to maintain oversight of every contract pharmacy relationship and to hire an independent audit firm to review each contract pharmacy at least once a year.
Contract pharmacies have become a major point of tension in the program. Several drug manufacturers have tried to restrict or refuse 340B pricing when covered entities use contract pharmacies rather than in-house dispensing. This has led to ongoing federal litigation, with courts weighing whether the original statute requires manufacturers to honor 340B prices regardless of how the drugs reach patients.
How Patients Benefit
If you fill a prescription at a 340B pharmacy, your experience may look identical to any other pharmacy visit. You hand over your prescription, show your insurance card if you have one, and pick up your medication. The 340B discount happens behind the scenes, between the drug manufacturer and the covered entity. Whether you personally see lower prices at the counter depends on the organization and your insurance status.
For uninsured and underinsured patients, the savings can be significant and direct. Federally qualified health centers, which make up a large share of 340B participants, are required to operate sliding fee discount schedules. Patients with household incomes at or below the federal poverty level receive a full discount on services, including medications. Partial discounts apply to those earning between 100% and 200% of the poverty level, with at least three graduated discount tiers. No one can be turned away for inability to pay.
For insured patients, the benefit is more indirect. The covered entity collects insurance reimbursement at standard rates but paid far less for the drug, generating a margin. That revenue funds services like behavioral health programs, dental care, patient transportation, translation services, and other resources that safety-net providers rely on to keep their doors open.
Compliance Rules and Restrictions
Two key rules govern 340B pharmacies. The first is the prohibition on diversion: 340B drugs can only go to patients of the covered entity. If a pharmacy dispenses a 340B-purchased drug to someone who isn’t an established patient of the participating organization, that’s a violation. The second is the ban on duplicate discounts. A covered entity cannot collect both a 340B discounted purchase price and a Medicaid rebate on the same drug. Federal law explicitly prohibits this double-dipping, and covered entities must have systems in place to prevent it.
Violations carry real consequences. Covered entities are subject to audits by HRSA, drug manufacturers, or both. If an audit uncovers noncompliance, the entity can be required to refund discounts to manufacturers and, in serious cases, can be removed from the program entirely.
Why the Program Is Controversial
The 340B program has grown substantially since its creation, and that growth has fueled debate. Hospitals and clinics argue the discounts are essential for funding care in underserved communities, particularly as the cost of specialty drugs continues to climb. Drug manufacturers counter that the program has expanded well beyond its original intent, with some large hospital systems using contract pharmacy networks to generate significant revenue without clear requirements to pass savings directly to patients.
There is no federal mandate specifying exactly how covered entities must use their 340B savings. HRSA estimates the program generates 25% to 50% savings on drug purchases nationally, but tracking where that money ultimately goes remains difficult. This lack of transparency sits at the center of most policy disagreements. Legislative proposals to add reporting requirements or tighten eligibility have circulated in Congress for years, though no major reform has been enacted.
For patients, the key takeaway is practical: if you receive care at a community health center, a qualifying hospital, or a specialized safety-net clinic, there’s a good chance your prescriptions are being filled through the 340B program. You may see lower out-of-pocket costs directly, or you may benefit from the expanded services your provider can offer because of the savings the program generates.